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JEFFREY M. FRIEDMAN 
Laboratory of Molecular Genetics, Howard Hughes Medical Institute, 
The Rockefeller University, New York, New York 
I. INTRODUCTION 
T
he assimilation, storage, and utilization of nutrient energy constitute
a complex homeostatic system essential for life. In vertebrates, and es­
pecially among land-dwelling mammalian species, the ability to store suf­
ficient quantities of energy-dense triglyceride in adipose tissue permits 
survival during the frequent periods of food deprivation often encoun­
tered during evolution. However, the presence of excess adipose tissue is 
maladaptive and renders obese organisms more susceptible to predation 
and less effective at hunting. In addition, the accumulation of excess adi­
pose tissue in humans increases the risk for developing hypertension, dia­
betes, and cardiovascular disease, all of which are major causes of 
morbidity. In order to regulate fuel stores and energy balance at an op­
timum level, a complex physiologic system has evolved. 
A number of lines of evidence support the hypothesis that body weight 
is regulated by a robust physiologic system. Twin studies, analyses of fa­
milial aggregation, adoption studies, and studies of animal models of obe­
sity all indicate that obesity is to a significant extent the result of genetic 
factors [1-3]. Moreover, there is abundant evidence that weight is ex­
tremely stable in lean and obese individuals [ 4]. This is despite the fact 
that a large proportion of the population actively practices some form of 
weight control. Still, dieting is not generally successful for long-term 
maintenance of a reduced body weight and the majority of reduced obese· 
individuals eventually regain the lost weight [5]. 
The relative stability of weight among most individuals has suggested 
that energy balan�e in mammals is controlled by a feedback loop that 
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maintains constancy of total body energy stores. This system is composed 
of three components: afferent signals that report nutritional information, 
a controller in the hypothalamus, and efferent signals that coordinately 
regulate food intake and metabolism [6]. Thus it has been suggested that 
signals that report nutritional state are sensed by the brain, specifically the 
hypothalamus, which in turn modulates food intake and energy expendi­
ture [7-9). However, the identification of these signals proved difficult 
and, indeed, for many decades their existence was widely questioned. In 
recent years, several of the key components of the system regulating body 
weight have been identified, in particular, leptin and the leptin receptor 
[10). These genes have human homologues and their functions are con­
served among mammalian species. 
II. AFFERENT SIGNALS
In the 1970s, a critical clue regarding the identity of a key nutritional 
signal was suggested by studies of mutant obese (obi ob) and diabetic 
(db/db) mice. Recessive mutations in the mouse ob and db genes result in 
obesity and diabetes in a syndrome resembling morbid human obesity [3, 
11]. Affected ob/ob and db/db mice have identical phenotypes, each mu­
tant weighing three times that of normal mice with a fivefold increase in 
body fat content. Data from cross-circulation (parabiosis) experiments 
suggested that the ob gene encoded (or was responsible for the generation 
of ) a circulating factor that regulated nutritional state and that the db gene 
encoded the receptor for this factor [3]. 
The successful cloning and characterization of the ob gene in 1994 has 
confirmed that it encodes a novel adipocyte-derived hormone. As the wild­
type ob gene is required to prevent obesity, its protein product was named 
"leptin" from the Greek word leptos, meaning thin. Further studies of leptin 
have led to the conclusion that body fat content is regulated by a negative 
feedback loop centered in the hypothalamus and elsewhere [12, 13) (Fig. 
1). The data further suggest that weight is regulated by a set point mecha­
nism and that weight is set at different levels among different individuals. 
When at the set point, a state of energy balance in which food intake equals 
energy expenditure is maintained. Increasing adipose tissue mass leads to 
an increase in leptin level. This in turn induces a state of negative energy 
balance until weight returns to the set point. A decreased adipose tissue 
mass is associated with a decrease in leptin level, which in turn induces a 
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state of positive energy balance. This system thus acts to maintain adipose 
tissue mass within a relatively narrow range. In addition, this system links 
changes in nutritional state to other physiologic systems (see below). 
Leptin circulates as a 16-kDa protein in mouse and human plasma but 
is undetectable in plasma from C57BL/6J ob/ob mice [14]. Leptin is not 
modified post-translationally as the molecular mass of the native protein 
is identical to that predicted by the primary sequence (without the signal 
sequence) [ 15]. The plasma levels of leptin is highly correlated with adi­







Fig. 1. Leptin and the regulation of adipose tissue mass. The cloning of the ob gene and 
the characterization ofleptin has suggested that body fat content is under homeostatic con­
trol. The available data suggest that leptin is the afferent signal in a negative feedback loop 
regulating adipose tissue mass. The level ofleptin is positively correlated with differences in 
body fat. Increasing leptin levels result in negative energy balance (energy expenditure < 
food intake) whereas decreasing levels lead to positive energy balance (food intake > energy 
expenditure). These effects maintain constancy of fat cell mass. The available data also sug­
gest that the hypothalamus is an important site of leptin action. 
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The levels of protein are increased in several genetic and environmentally 
induced forms of rodent obesity and in obese humans [13, 16-18]. 
Administration of leptin either by injection or as a constant subcuta­
neous infusion results in a dose-dependent decrease in body weight at in­
cremental increases of plasma leptin levels within the physiologic range 
[19-24]. The dramatic effect of leptin vs. saline treatment of ob mice is 
shown (Fig. 2). The potency of leptin is much higher when delivered as a 
constant infusion vs. bolus injections. This indicates that the mode of de­
livery may ultimately be a critical determinant of leptin's utility as a ther­
apeutic agent. In both ob/ob and wild-type mice, leptin induced weight 
loss is restricted to adipose tissue with sparing oflean body mass [14]. 
In aggregate, these data establish leptin's role as an afferent signal in a 
feedback loop modulating the size of adipose tissue mass. However, 
Fig. 2. Boch of these mice have a defect in the obese (ob) gene. This mutation usually re­
sults in a marked increase in the amount of fat. Administration of the protein encoded by 
the ob gene, called leptin, reduced the body weight of the ob mice. After 4.5 weeks, the ob 
mouse on the left, which did not receive lepcin, weighed approximately 67 g, whereas the 
mouse on the right, who received daily injections of lepcin, weighed 35 g. Normal mice 
weigh approximately 24 g, a weight equivalent co chat of an orange. Daily injections of 
leptin co ob mice reduced body weight via effects on food intake and energy expenditure, 
meaning the treated animals ace less and also burned more calories. 
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leptin is not the only afferent signal that regulates food intake and body 
weight. The systems that control feeding behavior and energy balance 
seem to be comprised of a short-term and long-term system. The short­
term system regulates meal pattern and feeding throughout the day. Pre­
vious work has indicated that changes in plasma glucose concentration, 
body temperature, plasma amino acids, cholecystokinin, and other hor­
mones can all modulate meal patterns [25, 26]. The long-term system 
balances food intake and energy expenditure and thus plays a dominant 
role in ultimately regulating the size of the body's energy stores. Leptin 
appears to function largely within the long-term system and influences 
the quantity of food consumed relative to the amount of energy that is 
expended. Leptin levels do not increase significantly after a meal and it 
does not, by itself, lead to the termination of a meal [16, 18]. These re­
sults suggest that leptin is not a classic satiety factor. However, leptin and 
the other components of the long-term system are likely to interact ex­
tensively with the components of the short-term system by modulating 
the amount of food that is consumed during a meal and/ or the likelihood 
that an organism will miss a meal. 
III. REGULATION OF LEPTIN PRODUCTION
The physiologic importance of quantitative changes in leptin concen­
tration suggests that regulation of the ob gene is an important control 
point. The level of ob gene expression per cell is highly correlated with the 
lipid content and the corresponding size of individual adipocytes [13]. 
Previous studies have suggested that differences in fat cell size can have an 
important impact on the weight of an organism [27]. The signal trans­
duction system by which fat cells sense their lipid content (possibly size) 
and in turn adjust the level of ob expression is unknown. Extrinsic factors 
also modulate the expression of leptin. Leptin levels increase -30% at 
night and, based on sampling of levels at 5-minute intervals, also seem to 
oscillate each hour [18, 28]. Although feeding does not seem to increase 
leptin expression, an extended fast acutely decreases plasma leptin con­
centration [16]. Other hormones also modulate ob gene expression 
including insulin, glucocorticoids, tumor nerosis factor (TNF), and inter­
Leukin-1 (IL-1) [29-33]. The ob promoter seems to be responsive to sev­
eral transcription factors including cEBP and PPARy [31, 34-36]. It is 
not known which other factors regulate the expression of ob RNA, nor is 
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it known whether leptin is released from adipocytes from storage vesicles 
or via the constitutive pathway of protein secretion. 
IV. A BROADER ROLE FOR LEPTIN
Leptin-deficient (ob/ob) mice manifest myriad endocrine and metabolic 
abnormalities [3]. Many of these derangements, which include decreased 
body temperature, hyperphagia, decreased energy expenditure (including 
activity), and infertility are also observed in starved animals. This has sug­
gested that in the absence of leptin, ob/ob mice exist in a state of perceived 
starvation and thus exhibit a constellation of signs that are characteristic of 
the starved state. Indeed, in circumstances where food is readily available, 
this biologic response would be expected to lead to the massive obesity ev­
ident in ob/ob mice. As predicted by such a model, replacement of leptin 
was found to correct all of the aforementioned abnormalities of mutant 
ob/ob mice [14, 21, 37]. 
The possibility that falling plasma leptin levels signal nutrient deprivation 
is further suggested by the observation that exogenous leptin attenuates the 
neuroendocrine responses to food restriction [38]. Fasted wild-type mice 
receiving leptin continue to ovulate whereas fasted controls given PBS expe­
rience an ovulatory delay of several days. Leptin treatment blunts the 
changes in circulating thyroid hormone and corticosterone levels that are 
normally associated with food deprivation [38]. Starvation is also associated 
with decreased immune function and leptin corrects these abnormalities 
[39]. Leptin stimulates proliferation of CD4+ T cells and increases produc­
tion of cytokines by T-helper-1 cells [39]. These results indicate that leptin 
may also be a key link between nutritional state and the immune system. 
Leptin is also important in regulating the onset of puberty. Extremely 
thin women often stop ovulating, and abnormally thin adolescent women 
enter puberty later than their heavier counterparts. These observations 
have suggested that reproductive capability in woman is suppressed in the 
absence of adequate nutritional stores. These findings have further sug­
gested that fat tissue may produce a signal that regulates reproduction 
[40]. This factor may be leptin. Treatment of prepubertal female mice 
with leptin accelerates the maturation of the female reproductive tract and 
leads to an earlier onset of the oestrous cycle and reproductive capacity 
[41, 42]. In humans, a surge in plasma leptin concentration is seen in pre­
pubertal females [ 43]. The evidence suggests that sufficient levels of leptin 
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are necessary but not sufficient for the onset of puberty. These studies sug­
gest that leptin modulates reproductive function and provides a direct link 
between reproduction and the nutritional status of an animal. 
These observations led to speculation that leptin's primary physiological 
role is to signal nutritional status during periods of food deprivation [26, 
44]. However, leptin's physiologic role in preventing weight gain has re­
cently received significant experimental support. As mentioned, lean mice 
given chronic infusions of leptin lose adipose mass in a dose-dependent 
fashion at leptin levels within the physiologic range [19, 45]. These data 
indicate that dynamic changes in plasma leptin concentration act to resist 
weight change in either direction. 
V THE LEPTIN RECEPTOR AND LEPTIN'S SITES OF ACTION 
The leptin receptor is a member of the cytokine family of receptors. 
These receptors have a single transmembrane domain and are generally ex­
pressed as monomers or dimers on the cell surface. Ligand binding induces 
dimerization and/ or activation of the receptor and activates signal trans­
duction. Ob-R is predicted to have two separate leptin binding regions and 
binds leptin with nanomolar affinity [46]. The stoichiometry of binding is 
not yet known, although the related granulocyte colony-stimulating factor 
(G-CSF) receptor also has two binding domains and binds to G-CSF with 
a ligand:receptor ratio of 2:2 [47]. 
There are several different forms of the leptin receptor, one expressed at 
a high level in choroid plexus and other tissues, known as Ob-Ra, and an­
other expressed in hypothalamus and elsewhere, known as Ob-Rb. Ob-Rb 
(also referred to as Ob-R-L) has a long cytoplasmic region with several 
motifs required for signal transduction [ 46, 48-51]. The other splice vari­
ants, ObRc-e, have also been identified. Ob-Ra is missing motifs generally 
required for signal transduction by this class of receptors. 
Mutations that disrupt the leptin receptor have been identified in each 
of the available alleles of genetically obese db mice as well as fa rats, the rat 
homologue of db [52]. In the C57BL/Ks db/db mutation, the Ob-Rb 
transcript is specifically mutant whereas the other splice variants are 
normal J48, 53]. This db mutation is the result of abnormal splicing 
leading to the insertion of a 106-bp fragment including a premature stop 
codin into the 3' end of Ob-I�.b RNA. The insertion is derived from the 
Ob-Ra 3' end and, as a consequence, the Ob-Ra protein is expressed in 
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place of Ob-Rb in this mouse strain. The phenotype of these C57BLKs 
db/db mice is indistinguishable from that of ob mice. As ObRb is the only 
form of the receptor that is deranged in these mutant mice, these data es­
tablish that Ob-Rb is absolutely necessary for leptin to exert its weight re­
ducing effects. Ob-Rb is normally expressed at a high level in the 
hypothalamus and other brain regions, T cells, and vascular endothelial 
cells and at a lower level in many other tissues [39, 48, 49, 54, 55]. 
The high level of Ob-Rb in hypothalamus suggests that this brain region 
is an important site of leptin action [ 48, 49]. In situ hybridization has iden­
tified the arcuate, DMH, paraventricular nucleus (PVN), VMH, and LH 
hypothalamic nuclei as the principal sites of Ob-Rb expression [52, 56, 
57]. These hypothalamic nuclei have all been shown to play a role in regu­
lating food intake and body weight [8]. Leptin is also expressed in other 
brain regions including the cortex, thalamus, and the limbic lobe [55]. Fur­
ther evidence in support of a hypothalamic site of action for leptin was sug­
gested by the observation that leptin induces a dose-dependent activation 
of the STAT3 transcription factor in the hypothalamus of mice within 15 
minutes of a single intraperitional injection [58]. STAT3 activation was not 
observed in any other tissues. Leptin also increases the level of expression of 
fos, a STAT3 target, and several other genes in the hypothalamus [59]. 
Defects in leptin signal transduction may also be important in the de­
velopment of leptin resistance. Studies of the function of the lepcin re­
ceptor in vitro have confirmed chat Ob-Rb is capable of activating signal 
transduction [49-51, 60]. The introduction of mutations into Ob-Rb 
have identified several sequences in the carboxy terminus chat are required 
for activation of different signal transduction pathways [50, 51]. These 
studies have indicated chat activation of the leptin receptor is dependent 
on phosphorylation of the JAK2 kinase after ligand binding co an Ob-Rb 
homodimeL Leptin also leads to the tyrosine phosphorylation of the SHP-
2, a phosphotyrosine phosphatase, which in turn decreases both the state 
ofJAK-2 phosphorylation and transcription of a leptin-inducible reporter 
gene [61, 62]. Thus, SHP-2 may play a role in shutting off the lepcin 
signal transduction pathway. SOCS-3, a suppressor of JAK signaling, has 
also been implicated in lepcin signal transduction and may also play a role 
in down-regulating the response co lepcin [63]. Ochp components of the 
lepcin signal transduction pathway have not yet been identified. 
The synaptic transmission of neurons from the arcuate nucleus is altered 
by lepcin [ 64]. Lepcin leads to the hyperpolarization of some hypothalamic 
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neurons and replicates the effect of glucose on these cells [ 65]. This effect is 
dependent on a KAJ"P channel as tolbutamide inhibits the effect [65]. These 
electrophysiologic effects are rapid aO:d are unlikely to require new tran­
scription via activation of STAT or other proteins. The components of the 
leptin signal transduction that alter electrical activity in neurons are not yet 
known and their identification could provide new therapeutic targets. 
The importance of the central nervous system (CNS) as a site ofleptin ac­
tion has also been assessed in comparisons between peripherally and centrally 
administered leptin. A single injection ofleptin ICV reduces food intake at 
doses that have no effect when delivered peripherally [19, 22, 23, 66]. 
Chronic infusion ofleptin ICV at a dose of 3 ng/hr results in total depletion 
of body adipose stores whereas peripheral administration requires doses 
greater than 500 ng/hr to achieve the same effect [19]. The effect of a 3 ng/hr 
ICV dose seems to be at the peak of the dose response curve as higher doses 
(50 and 500 ng/hr) have an identical effect. To date, all of the weight-re­
ducing and anorectic effects of peripheral leptin are reproduced by low-dose 
leptin infused into the III ventricle as are the effects of leptin on glucose and 
fat metabolism [ 19, 67, unpublished observation]. These data establish leptin 
as the most potent weight-reducing peptide known when delivered into the 
CSF and suggest that the CNS is a major site of leptin action. 
Leptin also acts on peripheral cell types and has direct mitogenic effects 
on CD4+ human T cells [39] (Fig. 3). Leptin has direct effects on endothe­
lial cells directly and increases angiogenesis, although high doses are required 
[54]. Leptin modulates pancreatic cell function in vivo and has direct effects 
on other cell types in vitro [ 68]. The leptin receptor is widely expressed, al­
though the Ob-Ra (short) form of the receptor predominates in many of 
these tissues [48, 49, 57]. Although the potency of i.c.v. leptin indicates that 
direct peripheral effects are not absolutely required for weight loss, the full 
spectrum of its actions is not known. It is thus possible that leptin acts on a 
variety of tissues and thus functions in other physiological systems. 
The importance of Ob-Ra expression or the other forms of the receptor 
in a particular tissue is not clear. Ob-Ra could function in the transport of 
leptin across the blood brain barrier or in clearance of the peptide from 
the CSF [ 46, 69]. At present, however, the mechanism of leptin transport 
into the CNS has not been elucidated. Ob-Ra may also serve functions· 
dishnct from Ob-Rb and could even form complexes with other cell sur­
face proteins that in turn respond to leptin. A soluble form of the leptin 
receptor, Ob-Re, has also been identified in mouse and human plasma 
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Fig. 3. Leptin is secreted from adipocytes either as a 16 kDa protein or bound to a sol­
uble form of its receptor. The level ofleptin is positively correlated with differences in body 
fat. Increasing leptin levels result in negative energy balance (energy expenditure < food in­
take) whereas decreasing levels lead to positive energy balance (food intake > energy expen­
diture). Leptin acts predominately on the hypothalamus. Extensive connections exist 
between the hypothalamus and other brain regions. Leptin acts centrally to decrease food in­
take and modulate glucose and fat metabolism. Peripheral effects on T cells, pancreatic islets, 
and other tissues have also been demonstrated. CVO, circumventricular organ. 
[ 62, 70]. The function of Ob-Re is unknown and experiments that test 
the effects of recombinant Ob-Re are necessary. In most cases, such as 
with the growth hormone and interferon, soluble receptors chelate the 
ligand and have inhibitory effects but in the case of CNTF, the soluble re­
ceptor can activate signal transduction [71-73]. 
VI. THE NEURAL CIRCUIT REGULATING WEIGHT 
The available data suggest that the concentration of leptin is sensed by 
groups of neurons in the hypothalamus and other brain regions. During 
starvation, leptin levels fall thus activating a behavioral, hormonal, and 
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metabolic response that is adaptive when food is unavailable. Weight gain 
increases plasma leptin concentration and elicits a different response 
leading to a state of negative energy balance. It is as yet unclear whether 
the same (or different) neurons respond to increasing vs. decreasing leptin 
levels. In addition, the spectrum of leptin's effects is likely to be complex 
as recent studies have indicated that different thresholds exist for several of 
leptin's effects [7 4]. 
As mentioned, various nuclei in the hypothalamus have been implicated 
in the control of food intake and their role with respect to leptin action has 
recently been examined. Leptin receptors have been localized to several of 
these hypothalamic nuclei including the arcuate, VMH, LH, DMH, and 
PVN [8, 52, 56, 57]. The LH and VMH project both within and outside 
the hypothalamus and modulate activity of the parasympathetic and sym­
pathetic nervous system, respectively [75]. The DMH also has inputs to 
the parasympathetic nervous system and has been implicated in integrating 
information among the VMH, LH, and PVN. The PVN controls secretion 
of peptides from both the posterior and anterior pituitary and projects to 
nuclei with sympathetic or parasympathetic efferents [75]. The PVN also 
projects to numerous sites outside of the hypothalamus including higher 
centers known to modulate motivational behaviors. 
Each of these hypothalamic nuclei express one or more neuropeptides 
and neurotransmitters that regulate food intake and/or body weight (Table 
I). Genetic evidence has implicated several of these neuropeptides as playing 
a role in the response to leptin and other nutritional signals. The data are 
consistent with the possibility that neuropeptide Y (NPY) and melanin­
concentrating hormone (MCH) play a role in the response to absent (and 
possibly low) leptin levels, whereas centrally expressed amelanocyte stimu­
lating hormone (aMSH), its MC-4 receptor, and the Agouti related tran­
script (ART also known as AGRP) play a role in the response to an increased 
plasma leptin concentration (Fig. 4) [76]. Differential effects ofleptin on 
neurons expressing either NPY or POMC have been reported [77]. Each of 
these molecules is expressed in the hypothalamus and in most instances 
other brain regions as well. What follows is a brief description of the func­
tional properties of these and other neuropeptides and neurotransmitters 
that have been suggested as being components of the neural circuit that reg-
, ulates food intake and/ or body weight. 
When administered intrathecally, NPY is the most potent orexigenic 
agent that is known. NPY RNA is increased in ob/ob mice and its levels 
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TABLE I. HYPOTHALAMIC MODULATORS OF Fooo INTAKE 





Orexin a and b 
Peptide YY 
Ghrelin 
Moradrenaline (a2 receptor) 











decrease after leptin tt:eatment [23]. An NPY knockout attenuates the 
obesity and other features of ob/ob mice indicating that it plays a role in 
the response to absent leptin. Data from other knockout mice indicate 
that both the Y2 and possibly Y5 receptors play a role in mediating some 
of NPY's effects on food intake and body weight [78-80]. 
aMSH as well as MSH agonists decrease food intake. Reduced signaling 
of MSH in genetically obese Nor MC-4R knockout mice results in obe­
sity and leptin resistance [19, 81, 82]. Leptin modulates POMC gene ex­
pression (POMC is the precursor of MSH) [83]. In addition, a subset of 
neurons express both Ob-R and POMC [84]. ART, an endogenous antag­
onist of melancortin signaling, is also implicated in the regulation of weight 
as transgenic mice overexpressing AGRP are markedly obese [85]. In addi­
tion, mRNA.for this hypothalamic peptide is increased eightfold in ob/ob
mice [86]. In aggregate, these results suggest that NPY may play a role in 
mediating the response to starvation, whereas melanocortin functions in 
the pathways that prevent obesity [23]. It is important to note, however, 
that these molecules are likely to respond to other signals and that these 
complex neural circuits are likely to interact with one another. 
MCH, a neuropeptide expressed in the lateral hypothalamus, is in­
creased in ob/ob mice and injections of it increase food intake in mice [87]. 
Mice with mutations of MCH are hypophagic and lean, thus confirming 
a role for this peptide in the maintenance of body weight [88]. MCH-
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Fig. 4. The neural circuit activated by leptin. In the arcuate nucleus of the hypothal­
amus, the leptin receptor is expressed in at least two different classes of neurons. One class 
expresses NYP and AGRP, two neuropeptides that increase food intake. Another class ex­
presses POMC, the precursor of aMSH and CART. Both CART and aMSH decrease food 
intake. The evidence suggests that leptin suppresses the activity ofNPY/AGRP neurons and 
stimulates the activity of POMC/CART neurons. Thus, in the absence of leptin the 
NPY/AGRP neurons are maximally active and food intake is stimulated. In the presence of 
increased leptin levels, the POMC/CART neurons are maximally active and food intake is 
reduced. When an individual is at their stable weight the activity of these pathways is bal­
anced. The neural mechanisms by which these neurons change food intake is not known. 
Figure credit: Lex von der Plueg, Merck Pharmaceuticals. 
expressing neurons receive inputs from NPY neurons in the arcuate nu­
cleus and appear to relay NPY's orexigenic signal. MCH and MSH posi­
tive neurons in turn project to many of the same brain regions as aMSH 
and these molecules have opposite effects in food intake. Both act via dis­
tinct receptors and MSH increases whereas MCH decreases cAMP sig­
naling. Thus the plasma leptin concentration influences the relative 
activity of anorexigenic and orexigenic circuits. 
Many other neurotransmitters and neuropeptides are likely to function 
in this homeostatic system (Table I) [IO]. These molecules respond to a 
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number of nutritional signals, and it is likely that leptin, glucose levels, 
and other signals potentiate the action of some of these anorexogenic 
agents and antagonizes the orexigenic (i.e., stimulates food intake) of 
others. Indeed, many leptin receptor-expressing neurons also express one 
or more of these mediators (84]. T hese are briefly reviewed here. 
Cholecystokinin (CCK) was the first neuropeptide suggested to play a 
role in regulating food intake (89]. Injections of CCK increase satiety in 
food deprived rats via afferent vagal nerves (90]. Recently, CCK was re­
ported to potentiate the anorectic effect of leptin (91]. 
CART, a hypothalamic peptide, is also implicated as playing a role in 
the response to leptin [92]. CART decreases food intake, its antibodies in­
crease food intake, and its mRNA is increased in ob/ob mice. In addition, 
CART co-localized with aMSH in some hypothalamic neurons. 
Bombesin also reduces food intake and induced mutations of the 
bombesin 3 receptor result in mild obesity (93]. A growing body of evidence 
indicates that insulin acts on the hypothalamus to decrease food intake [94]. 
Two recently identified neuropeptides, orexin-a and orexin-b, also regulate 
the state of an animal's arousal but may also modulate food intake [95, 96]. 
Corticotropin-releasing factor (CRF) is another factor that is likely to 
mediate some of leptin's effects. CRF is expressed at high levels in the 
PVN and in the amygdala, which projects to the LH [97, 98]. Addition­
ally, the DMH has CRF-containing neurons (99]. CRF regulates pituitary 
adrenocorhicotropic hormone (ACT H) release and adrenal glucocorticoid 
secretion. Delivery of CRF to the PVN also results in reduced food intake 
and increased energy expenditure in lean and obese rodents [100, 101]. 
Leptin has been shown to increase CRH mRNA in the PVN and to stim­
ulate release of CRF from perfusion slices of both amygdala and the PVN 
[102, 103]. Leptin may also inhibit the increase in CRH evident during a 
stress response [104]. 
Glucocorticoids have long been known to play a role in regulating body 
weight. Increased fat deposition is a feature of Cushings syndrome, and in­
creased glucorticoids result in obesity in mice [105]. High levels of gluco­
corticoids are also observed in most strains of genetically obese mice. 
Moreover, adrenalectomy and glucocorticoid antagonists blunt the obesity 
evident in ob/ob, db/db, and other obese mice [106, 107]. Low-dose glu­
corticoid replacement restores the obese phenotype of adrenalectomized 
ob/ob mice, indicating that they play a permissive role in the development 
of the obese phenotype [107]. It is unclear whether the requirement for 
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glucocorticoids in the development of the full ob/ob phenotype depends 
on the suppression of CRH, a known effect of glucocorticoids, or if an­
other mechanism is operative. 
The functional relationship of these orexigenic and anorexigenic agents 
is likely to have therapeutic implications. Antagonists of NPY and its re­
ceptors are currently under development as are agonists of the MC4 re­
ceptor [108]. Serotonin, which reduces food intake, and norepinephrine, 
which is orexigenic, are both targets for known weight-reducing agents 
such as fen-fen (dexfenfluramine and phentermine). A knockout of the 
HT2c form of the serotonin receptor leads to a form of mild obesity [109]. 
Future opportunities for the development of antiobesity agents may de­
pend on progress toward understanding the functional relationship among 
these and other components of this neural circuit that regulates weight. 
VIL EFFERENT PATHWAYS REGULATING METABOLISM 
The evidence indicating that leptin can act centrally to modulate body 
weight raises the following question: How does the CNS regulate periph­
eral metabolism in response to differences in leptin concentration? 
Whereas increasing leptin levels lead to fatty acid oxidation and a reduc­
tion in adipose tissue mass, leptin deficiency, evident in ob/ob mice or mice 
receiving a leptin anatgonist, is associated with an increase in fat deposi­
tion [3, 11 O]. In ob/ob mice, the rate of lipogenesis is markedly increased 
as is the abundance of the RNAs encoding the enzymes that are rate lim­
iting in fatty acid synthesis [3, 111]. It as yet unclear whether the meta­
bolic derangements of ob mice are solely the result of increased food intake 
or if other factors are also important. 
The mechanism by which centrally administered leptin leads to lipo­
lysis and the loss of adipose tissue mass is similarly unclear. The available 
evidence suggests that the metabolic response to leptin is markedly dif­
ferent from the response to reduced food intake. Whereas food restriction 
(i.e., dieting) leads to the loss of both lean body mass and adipose tissue 
mass, leptin-induced weight loss is specific for the adipose tissue mass [14, 
19, 20]. Leptin also prevents the reduced energy expenditure normally as­
sociated with a decreased food intake [19]. Finally, hyperleptinemic ani­
mals undergoing a rapid period of weight loss fail to show any rise in 
serum-ftee fatty acids or ketones [112]. This is in contrast to food­
restricted (pair-fed) animals, which show a marked rise in serum-free fatty 
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acids. Indeed, despite the fact that the respiratory quotient falls after leptin 
treatment (indicative of fatty acid oxidation), the metabolic fate of stored 
triglycerides in adipose tissue is unknown [ 19]. 
Leptin also has novel effects on glucose metabolism. The possibility that 
leptin modulates glucose metabolism was first suggested in studies of ob/ob
mice treated with leptin. ob/ob mice are diabetic, and the severity of the di­
abetes is dependent on the background strain carrying the mutation [3]. In 
one study, leptin normalized the hyperglycemia and hyperinsulinemia evi­
dent in C57BL/6J ob/ob mice at doses that did not decrease weight [21]. 
Antidiabetic effects have also been observed in insulin-deficient rats [113]. 
Leptin also corrects the insulin resistance and hyperglycemia evident in a 
lipodystrophic transgenic mouse line [114]. These data confirm that leptin 
has novel and clinically relevant effects on glucose metabolism. 
The mechanisms by which the CNS regulates fat and glucose metabo­
lism in response to leptin are also unknown. Given the dense concentra­
tion of leptin receptor in the hypothalamus, there are two general 
possibilities. One is that a releasing hormone is secreted into the hy­
pophyseal portal system and acts to stimulate secretion of a pituitary hor­
mone (known or unknown). Alternatively, leptin may activate a neural 
effector pathway(s) that modulates fat and glucose metabolism. The 
former seems unlikely as hypophysectomized and adrenalectomized rats 
still lose copious amounts of weight after administration of centrally 
infused leptin [33; unpublished data]. Furthermore, corticosterone and 
thyroid hormone levels do not change in hyperleptinemic animals ( un­
published data). Direct measurement of nerve activity has indicated that 
infusion of leptin increases sympathetic activity to brown adipose tissue, 
kidney, hind limb, and adrenal gland [115, 116]. It is not yet known 
whether blockade of beta adrenergic receptors attenuates (or blocks) 
leptin-induced weight loss. Thus, although ICY leptin seems to modulate 
the activity of the SNS, the role of the SNS in mediating the weight re­
ducing effect of leptin is not established. 
VIII. PATHOGENESIS OF OBESITY
In principle, alterations in body weight could be the result of abnormal­
ities in the generation of the aforementioned afferent signals, the cells that 
receive the signal or the efferent pathways that effect changes in weight. 
Thus, the pathogenesis of obesity can be inferred in a general way by mea-
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surement of the plasma leptin levels (Fig. 5). An increase in plasma levels 
suggests that obesity is the result of leptin resistance. A low or normal 
plasma concentration of leptin in the context of obesity suggests decreased 
production of leptin. This interpretation is similar to that relating insulin 
to the pathogenesis of diabetes. However, this designation is quite general, 
as a great number of hormones as well as genetic, environmental, and even 
psychologic factors influence leptin sensitivity and production. 
Plasma leptin levels have been measured in rodents and humans using 
both radio-immunoassay (RIA) and enzyme-linked immunoassay 
(ELISA) [16, 18]. In all forms of rodent obesity studied, the obese animals 
have higher leptin levels than controls (not including obi ob mice) [ 16, 17]. 
The data suggest that these forms of animal obesity are associated with 
leptin resistance. In each of three cases that have been tested, obese ani­
mals that are hyperleptinemic are indeed resistant to exogenous leptin 
(complete or partial), suggesting that their obesity is the result of leptin re­
sistance [19]. Diet-induced obese (D10) mice are only partially leptin re­
sistant and lose moderate amounts of weight at high doses. AY mice are 
completely resistant to high ICY doses of leptin and thus appear to have 
a defect in the neural circuit that is activated by leptin. Indeed, the insen­
sitivity of N mice to leptin strongly suggests that normal function of the 
MC-4 receptor is required for the response to exogenous leptin. NZO
mice are resistant to peripherally administrated leptin but respond nor­
mally to centrally administered leptin. Thus, in NZO (and possibly D10)
mice, leptin resistance may be the result of decreased transport of leptin
into the brain [ 19, 117]. This raises the possibility that differences in the
access of leptin to the brain could be important in the pathogenesis of
some forms of obesity. Consistent with this possibility, the levels of CSF
leptin in obese humans seems to plateau at high plasma leptin concentra­
tions [118, 119].
Mutant fat and tubby mice are also hyperleptinemic [16]. The basis for 
the apparent leptin resistance in these mice is unclear. Carboxypeptidase E 
(CPE), the gene product of the fat locus, alters post-translational pro­
cessing of many peptides including insulin, neurotensin, POMC, and 
MCH [120, 121]. The identity of the substrates of CPE that regulate 
weight and lead to obesity when these enzymes are defective is not known. 
The tub gene product is expressed at high levels in the PVN of the hypo­
thalamus [122, 123]. As mentioned, neurons in the arcuate nucleus, LH, 






















Fig. 5. Pathogenesis of obesity. There are three general ways in which alterations of the 
leptin regulatory loop could lead to obesity. (a) Failure to produce leptin, as occurs in ob/ob 
mice, would result in obesity, as would (b) inappropriately low leptin secretion for a given 
fat mass. In the latter case, the fat mass would expand until "normal" leptin levels are 
reached, resulting in obesity (also see Fig. ?). (c) Finally, obesity could result from relative or 
absolute insensitivity to leptin at its site of action. Such resistance would be associated with 
increased circulating leptin, analogous to the increased insulin levels seen with insulin­
resistant diabetes. In general, high plasma leptin levels are evident in obese rodents and hu­
mans. In a subset of cases, obesity is associated with normal levels of leptin. Differences in 
leptin production and leptin sensitivity could be the result of genetic, environmental and 
psychological factors. 
(75]. Further studies may reveal the link between this gene product and 
the leptin response. 
The leptin resistance observed in D10 mice emphasizes the fact that 
environmental factors can modulate leptin sensitivity (19, 117]. Akr mice 
(and some other strains) remain lean when fed a standard chow diet but 
become obese when fed a high-fat diet. However, other mouse strains do 
not become obese when exposed to an identical diet. This indicates that 
the pathogenesis of diet-induced obesity is the result of an interaction be­
tween genetic and environmental factors. A fuller understanding of the 
mechanisms by which fat content in the diet modulates weight is likely to 
be relevant to human obesity as the incidenct of obesity increases in many 
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populations in proportion when exposed to a high-fat, "Western" diet 
[ 124]. How might genes interact with environmental factors to cause obe­
sity? As travelers to France well know, exposure to a highly palatable diet 
often leads to transient weight gain. In most cases, the gained weight is 
rapidly lost. However, it is possible that in some cases, the induced in­
crease in endogenous leptin level (which accompanies weight gain) leads 
to a down-regulation of the leptin response and a failure to return to the 
starting weight. If tachyphylaxis to increased leptin is influenced by ge­
netic factors, one might predict that a subset of individuals (and some 
populations) would be especially susceptible to diet-induced obesity. The 
observation that animals that express constitutive levels of leptin are in­
sensitive to a high-fat diet supports this possibility. However, alternative 
explanations are possible and additional studies are required. Studies to 
identify the AKR alleles that predispose to diet-induced obesity may illu­
minate the underlying mechanism [125, 126]. 
IX. LEPTIN AND HUMAN OBESITY 
In human subjects, a highly significant correlation between body fat 
content and plasma leptin concentration has been observed, and obese hu­
mans generally have high leptin levels [ 16, 18]. These data suggest that, in 
most cases, human obesity is likely to be associated with insensitivity to 
leptin. However, 5-10% of obese human subjects have relatively low levels 
of leptin [ 16, 18]. Low leptin levels also predispose to weight gain in pre­
obese Pima Indians [127]. These data suggest that, in some instances, obe­
sity results from a subnormal secretion rate of leptin from fat. 
The basis for leptin resistance in the overwhelming majority of obese, 
hyperleptinemic human subjects is unknown. Data from studies of ani­
mals clearly indicate that this condition is likely to be very heterogeneous 
and that many factors are likely to influence the activity of the neural cir­
cuit that regulates feeding behavior and body weight and/or leptin trans­
port into the CNS. It has been suggested that entry of leptin into the CSF 
may be limiting in some obese subjects [118, 119]. If true, the develop­
ment of morbid obesity later in life could result when the plasma leptin 
levels exceed the capacity of the transport system. Treatment with recom­
binant leptin leads to an increase in CSF leptin concentrations in humans 
[128]. Leptin uptake has been demonstrated in the capillary endothelium 
of mouse and human brain and is decreased in preobese animals [69, 129, 
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130]. It has thus been proposed that transport across the brain capillary 
endothelium is required for leptin to find its way to its site of action in the 
brain interstitial space and that Ob-Ra and/or other proteins mediate 
leptin transport [ 69]. Moreover, defects anywhere in this transport 
pathway could lead to the development of obesity. 
Leptin resistance in humans is likely to be the result of a complex inter­
play of many factors. In principle, leptin resistance could result from al­
tered activity of any of the aforementioned components of the leptin 
signal transduction pathway. Factors that directly modulate energy expen­
diture or activate adipogenesis and lipogenesis could also result in ap­
parent leptin resistance. Finally, leptin's actions are likely to be influenced 
by psychological factors via connections between the higher cortical cen­
ters that modulate an animals motivational state and neural circuits within 
the hypothalamus. The neuroanatomic and functional relationships be­
tween these brain regions are not well understood. 
X. MUTATIONS ASSOCIATED WITH HUMAN OBESITY 
In almost all cases, obese subjects express at least some leptin, an obser­
vation that suggested that human ob gene mutations are likely to be rare. 
Recently, two cousins born from an extended family have been found to 
be homozygous for a frameshift mutation in the leptin gene. These indi­
viduals do not have any circulating leptin [ 131]. In these two subjects, the 
mutation is associated with profound obesity, suggesting that leptin is of 
critical importance for the control of body weight in humans. Affected 
members of a Turkish kindred with a missense mutation in the leptin gene 
also manifest extreme obesity and amenorrhea, which further suggests that 
leptin also plays a role in modulating reproductive function [132]. Similar 
conclusions were reached in studies of three massively obese members of a 
French family carrying mutations in the leptin receptor [133]. These three 
studies also indicate that, apart from severe obesity and abnormalities of 
reproductive function, the other abnormalities identifiable in ob and db
mice such as hypercortisolemia, cold intolerance, and severe diabetes are 
not necessarily apparent. The heterozygous members of these families are 
of normal weight. 
The association of massive obesity with mutations in leptin and its re­
., ceptor in humans confirms its importance in regulating body weight. This 
assertion is supported by data from early clinical trials in humans (see 
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below). However, mutations in these genes and other human genes in­
cluding POMC, PC-1, and the MC4 receptor are relatively rare [10]. Thus, 
the pathogenesis of most human obesity is largely unknown. It is likely that 
some of the genes responsible for human obesity in the general population 
will modulate either leptin secretion or leptin sensitivity. Both genetic and 
physiologic studies will be required to confirm this prediction in humans. 
XI. PROSPECTS FOR NEW TREATMENTS FOR HUMAN OBESITY
One important issue relevant for any treatment for obesity concerns the 
therapeutic endpoint. The health risk of obesity is greatly diminished when 
even modest amounts of weight (i.e., 5% of total weight) are lost [134, 
135]. This is the result of a marked improvement in the diabetic, hyperten­
sive, and cardiovascular status of obese subjects affected by these conditions 
[134]. Dieting by itself is only rarely effective for the long-term maintenance 
of weight loss, emphasizing the need for additional therapies [5]. Clearly, an 
important indication for leptin treatment would be for the management of 
the co-morbiditys associated with obesity. A recent prospective epidemio­
logic study of more than one million individuals has confirmed that obesity 
is an independent risk factor for increased mortality [136]. This finding am­
plifies the need for efficacious and safe means for treating this disorder. 
The possible therapeutic benefit of leptin treatment in humans is now 
being tested in several clinical settings. It is has been demonstrated that 
leptin therapy has potent weight-reducing effects in the two leptin­
deficient individuals that have been treated thus far [ 13 7]. In addition to 
reducing food intake, weight, and body fat content, the hormone also 
stimulated cycling of gonadotropins in one of the prepubescent 11-year­
old children receiving it. The efficacy of treatment with exogenous leptin 
in these subjects confirms that leptin plays a physiologic role to regulate 
weight in humans and also establishes a link between leptin signaling and 
reproductive capacity [ 13 7]. 
Recent data from early clinical trials in the general population have 
demonstrated that 4 weeks of leptin injections are safe and cause small but 
significant weight loss in lean and obese subjects compared with placebo 
(p < .02) (unpublished observation). Treatment of a subset of eight obese 
subjects for a total of 6 months resulted in an average weight loss of 7.1 kg 
in a group receiving 0.3 mg/kg leptin vs. 1.7 kg in a group receiving 
placebo. Some of the subjects in this group lost substantial amounts of 
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weight whereas others did not. This limited study suggests that leptin 
could ultimately emerge as an effective therapy for some obese subjects, al­
though studies of more patients are clearly required (138]. 
Further studies to determine the possible utility of leptin for the treat­
ment of Type II diabetes are also indicated, as animal studies suggest that 
leptin can increase glucose metabolism independent of weight (21, 67, 
139]. It is also possible that leptin could be of therapeutic benefit for the 
maintenance of weight loss after a diet (rather than as a means to induce 
weight loss). In humans, diet-induced weight loss results in a decrease in 
plasma leptin concentration (16]. This provides a possible explanation for 
the high failure rate of dieting, as a low leptin level is likely to be a potent 
stimulus for weight gain. Thus, leptin treatment after a very low calorie 
diet (VLCD) could, in principle, reduce the 95% failure rate of diets for 
long-term maintenance of weight loss. Further studies should reveal 
whether leptin is of therapeutic value in some obese subjects. 
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